
Kausik Datta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1756686/publications.pdf Version: 2024-02-01



KALISIK DATTA

#	Article	IF	CITATIONS
1	A Multicenter, Longitudinal Cohort Study of Cryptococcosis in Human Immunodeficiency Virus–negative People in the United States. Clinical Infectious Diseases, 2020, 70, 252-261.	5.8	68
2	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. Journal of Antimicrobial Chemotherapy, 2020, 75, 221-228.	3.0	6
3	Development and Evaluation of a Fully Automated Molecular Assay Targeting the Mitochondrial Small Subunit rRNA Gene for the Detection of Pneumocystis jirovecii in Bronchoalveolar Lavage Fluid Specimens. Journal of Molecular Diagnostics, 2020, 22, 1482-1493.	2.8	14
4	Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis. Clinical Infectious Diseases, 2018, 67, 1705-1711.	5.8	36
5	Immunotherapy of Fungal Infections. , 2017, , .		0
6	Immunotherapy of Fungal Infections. , 2017, , 468-497.		0
7	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 2938-2944.	3.0	15
8	Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity. Journal of Visualized Experiments, 2015, , e52216.	0.3	13
9	Immunotherapy of Fungal Infections. Immunological Investigations, 2015, 44, 738-776.	2.0	28
10	1433Diagnosis of Latent Histoplasmosis Using Interferon-Î ³ Release Assays. Open Forum Infectious Diseases, 2014, 1, S377-S377.	0.9	0
11	Host Defense Against Cryptococcal Disease: Is There a Role for B Cells and Antibody-Mediated Immunity?. Current Fungal Infection Reports, 2014, 8, 287-295.	2.6	5
12	Isavuconazole Activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, Emerging Fungal Pathogens with Reduced Azole Susceptibility. Journal of Clinical Microbiology, 2013, 51, 3090-3093.	3.9	37
13	Niche-Specific Requirement for Hyphal Wall protein 1 in Virulence of Candida albicans. PLoS ONE, 2013, 8, e80842.	2.5	34
14	Cystic Fibrosis Transmembrane Conductance Regulator Regulates Epithelial Cell Response to <i>Aspergillus</i> and Resultant Pulmonary Inflammation. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 301-310.	5.6	74
15	Cryptococcus gattii Infection in Healthy Hosts: A Sentinel for Subclinical Immunodeficiency?. Clinical Infectious Diseases, 2012, 54, 153-154.	5.8	45
16	Detection of Urinary Excreted Fungal Galactomannan-like Antigens for Diagnosis of Invasive Aspergillosis. PLoS ONE, 2012, 7, e42736.	2.5	55
17	The Absence of Serum IgM Enhances the Susceptibility of Mice to Pulmonary Challenge with <i>Cryptococcus neoformans</i> . Journal of Immunology, 2010, 184, 5755-5767.	0.8	95
18	Improved Survival of Mice Deficient in Secretory Immunoglobulin M following Systemic Infection with <i>Cryptococcus neoformans</i> . Infection and Immunity, 2010, 78, 441-452.	2.2	18

KAUSIK DATTA

#	Article	IF	CITATIONS
19	Spread of <i>Cryptococcus gattii</i> into Pacific Northwest Region of the United States. Emerging Infectious Diseases, 2009, 15, 1185-1191.	4.3	239
20	<i>Cryptococcus gattii</i> : Emergence in Western North America: Exploitation of a Novel Ecological Niche. Interdisciplinary Perspectives on Infectious Diseases, 2009, 2009, 1-8.	1.4	47
21	Therapeutic Efficacy of a Conjugate Vaccine Containing a Peptide Mimotope of Cryptococcal Capsular Polysaccharide Glucuronoxylomannan. Vaccine Journal, 2008, 15, 1176-1187.	3.1	40
22	Towards a vaccine forCryptococcus neoformans: principles and caveats. FEMS Yeast Research, 2006, 6, 525-536.	2.3	49
23	Protective and Nonprotective Human Immunoglobulin M Monoclonal Antibodies to Cryptococcus neoformans Clucuronoxylomannan Manifest Different Specificities and Gene Use Profiles. Infection and Immunity, 2004, 72, 4810-4818.	2.2	53
24	Serotype distribution ofCryptococcusneoformansin patients in a tertiary care center in India1. Medical Mycology, 2004, 42, 181-186.	0.7	29
25	Immunogenicity and Efficacy of Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice. Infection and Immunity, 2004, 72, 196-208.	2.2	59
26	Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan. Vaccine, 2004, 22, 4062-4068.	3.8	14
27	Fluconazole and itraconazole susceptibility ofclinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care. Journal of Antimicrobial Chemotherapy, 2003, 52, 683-686.	3.0	47
28	Species-specific Prevalence of Vaginal Candidiasis Among Patients with Diabetes Mellitus and its Relation to their Glycaemic Status. Journal of Infection, 2000, 41, 162-166.	3.3	109